<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Aachen_Lab_Methanol_Monocistronic_Diversity_Library skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Aachen/Lab/Methanol/Monocistronic Diversity Library</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="wrapper"><DIV id="main" class="clearfix"><NAV class="navbar navbar-default"><DIV class="dropdownbar"><DIV class="fluid-container"><DIV class="collapse navbar-collapse"><UL id="menu-header" class="nav navbar-nav navbar-left"><LI class="dropdown"><A href="#" data-toggle="dropdown" class="dropdown-toggle">Project</A></LI><LI><A class="menu-link" href="/Team:Aachen/InteractiveTour10">Interactive Journey</A></LI><LI><A class="menu-link" href="/Team:Aachen/Project/Overview">Overview</A></LI><LI><A class="menu-link" href="/Team:Aachen/Project/Background">Background</A></LI><LI><A class="menu-link" href="/Team:Aachen/Project/Outlook">Outlook</A></LI></UL><LI class="dropdown"><A href="#" data-toggle="dropdown" class="dropdown-toggle">Lab</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Lab">Overview</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Modeling">Modeling</A></LI><LI id="" class="dropdown"><A class="menu-link" href="/Team:Aachen/Lab/Methanol">Methanol</A></LI><LI><A href="/Team:Aachen/Lab/Methanol/Biobricks">Biobricks</A></LI><LI><A href="/Team:Aachen/Lab/Methanol/Polycistronic_Expression_Plasmid">Polycistronic Expression Plasmid</A></LI><LI><A href="/Team:Aachen/Lab/Methanol/Monocistronic_Diversity_Library">Monocistronic Diversity Library</A></LI><LI><A href="/Team:Aachen/Lab/Methanol/Characterization">Characterization</A></LI><LI id="" class="dropdown"><A class="menu-link" href="/Team:Aachen/Lab/Glycogen">Glycogen</A></LI><LI><A href="/Team:Aachen/Lab/Glycogen/Synthesis">Synthesis</A></LI><LI><A href="/Team:Aachen/Lab/Glycogen/Knockouts">Knockouts</A></LI><LI><A href="/Team:Aachen/Lab/Glycogen/Characterization">Characterization</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Lab/Libraries">Libraries</A></LI><LI id="" class="dropdown"><A class="menu-link" href="/Team:Aachen/Lab/Bioreactor">Bioreactor</A></LI><LI><A href="/Team:Aachen/Lab/Bioreactor/Hardware">Hardware</A></LI><LI><A href="/Team:Aachen/Software">Software</A></LI><LI><A href="/Team:Aachen/Lab/Bioreactor/Characterization_of_Bioreactor">Characterization</A></LI><LI class="dropdown"><A href="#" data-toggle="dropdown" class="dropdown-toggle">Notebook</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Notebook/Protocols">Protocols</A></LI><LI class="dropdown" id=""><A class="menu-link" href="/Team:Aachen/Notebook/Documentation">Documentation</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Notebook/Construction_Manuals">Construction Manuals</A></LI><LI class="dropdown"><A href="#" data-toggle="dropdown" class="dropdown-toggle">Human Practice</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Practices/Overview">Overview</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Practices/Maker_Faire">Maker Faire</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Practices/Community_Labs">Community Labs</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Practices/tubefront">tubefront</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Practices/Safety">Safety</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Collaborations">Collaborations</A></LI><LI class="dropdown"><A href="#" data-toggle="dropdown" class="dropdown-toggle">Achievements</A></LI><LI><A class="menu-link" href="/Team:Aachen/Achievements#Judging">Judging</A></LI><LI><A class="menu-link" href="/Team:Aachen/Parts">Parts</A></LI><LI class="dropdown"><A href="#" data-toggle="dropdown" class="dropdown-toggle">Team</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Attributions#Members">Members</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Attributions#Partners">Partners</A></LI><LI id=""><A class="menu-link" href="/Team:Aachen/Attributions#Attributions">Attributions</A></LI></DIV></DIV></DIV></NAV><DIV class="container tour"><DIV class="tourBoundingBox" style="display:none;"><DIV class="tourBoundingBoxInner"><DIV class="parentTourItem "><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour10">
					The Challenge
				</A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour20">
					The Team
				</A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour31">
					The Strategy
				</A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour31">
							Biological Approach
						</A></DIV><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour32">
							The Bioreactor
						</A></DIV></DIV></DIV><DIV class="parentTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour41">
					The People
				</A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour41">
							Maker Faire
						</A></DIV><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour42">
							Community Labs
						</A></DIV><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour43">
							tubefront
						</A></DIV></DIV></DIV><DIV class="parentTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour51">
					The Solution
				</A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour51">
							Engineering
						</A></DIV><DIV class="childTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour52">
							Biology
						</A></DIV></DIV></DIV><DIV class="parentTourItem"><A class="tourItemLabel" href="/Team:Aachen/InteractiveTour60">
					The Future
				</A></DIV></DIV></DIV></DIV><DIV class="container container-primary"><DIV class="row"><P>
Within our polycistronic methanol conversion construct the expression of the four genes <I>mdh</I>, <I>hps</I>, <I>phi</I> and <I>xpk</I> is controlled by the constitutive promoter <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A>. To tune the expression levels of the genes for a more efficient expression system it is neccessary to control them seperately. 
</P><P>
We decided to adjust the expression levels of the four genes by using well-characterized constitutive promoters with different strengths from the Anderson Promoter Library.
</P><P>
Since we do not know which promoter combination is best for the efficient expression of the methanol uptake pathway, we developed a straightforward cloning strategy to build a monocistronic diversity library using the RDP Assembly standard.
</P><DIV class="figraw figure-large col-md-6"><TABLE><TBODY><TR><TD><B>Monocistronic methanol conversion plasmid</B>The general design of a monocistronic methanol uptake plasmid. Later on we will introduce the design of a monocistronic diversity library, that varies in the promoter sequences prior to <I>hps</I>, <I>phi</I> and <I>xpk</I>.
<P>(Mdh = methanol dehydrogenase, Hps = 3-hexulose-6-phosphate, Phi = 6-phospho-3-hexuloisomerase, Xpk = phosphoketolase)
</P></TD></TR></TBODY></TABLE></DIV><H1><SPAN class="mw-headline" id="Design">Design</SPAN></H1><P>The design of our monocistronic diversity library is mainly based on the RDP Assembly method by Synbiota. To better understand our design, we recommend to first read our <A href="/Team:Aachen/Notebook/Protocols#RDP_Assembly" title="Team:Aachen/Notebook/Protocols">detailed description</A> about how the RDP assembly method works.
</P><P>
Because we expected the promoter <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A> to be the strongest within the Anderson Promoter Library, we chose this one to always control the bottleneck enzyme Mdh in our circuit design. Diversity is introduced by varying the promoters for the three remaining genes <I>hps</I>, <I>phi</I> and <I>xpk</I>. We decided on a set of four promoters from the Anderson Library:
</P><UL><LI><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23100">BBa_J23100</A></LI><LI><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23104">BBa_J23104</A></LI><LI><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23110">BBa_J23110</A></LI><LI><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A></LI></UL><P>
These promoters cover a range from medium to very high in strength.
</P><P>To minimize the genetic instability of our circuit <SUP id="cite_ref-1" class="reference"><A href="#cite_note-1">[1]</A></SUP>, we designed it to have four different terminator sequences downstream to every CDS. 
</P><P>
With three sites to introduce diversity in our circuit and (only) four different promoters, our resulting diversity library contains 4<SUP>3</SUP> = 64 variants. Obviously, it is nearly impossible for an iGEM team to clone every single variant seperately during one summer.
</P><P>
Our first step towards an efficient cloning strategy was to split up the circuit into RDP part fragments. To introduce diversity we first planed to add equimolar promoter RDP part mixes at the black labeled sites in the circuit.
</P><DIV class="figraw figure-large col-md-6"><TABLE><TBODY><TR><TD><B>Monocistronic diversity library RDP circuit</B>The circuit is composed by RDP parts. The black labled sites demonstrate, where we planed to introduce diversity by adding equimolar promoter part mixes during the assembly.
<P>(#FO4B#: Kanamycin anchor, #XYD9#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A> RDP part, #PRDW#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585210">BBa_K1585210</A> RDP part, #PLTB#: trp terminator RDP part, #VO4C#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585211">BBa_K1585211</A> RDP part, #8AMS#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B1006">BBa_B1006</A> RDP part, #ZALV#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585212">BBa_K1585212</A> RDP part, #HTSR#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B1002">BBa_B1002</A> RDP part, #ZR1Q#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585213">BBa_K1585213</A>.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B0015">BBa_B0015</A> RDP part, #OZD1#: high copy cap)
</P></TD></TR></TBODY></TABLE></DIV><P>
But to reduce the assembly steps and increase the assembly efficiency we decided to respectively combine three RDP parts from the circuit to form three different precursor sets.  
</P><DIV class="figraw figure-large col-md-6"><TABLE><TBODY><TR><TD><B>Precursor sets</B>One precursor set always consists of:
<OL><LI><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B0034">BBa_B0034</A> + CDS RDP part</LI><LI> the appropriate terminator RDP part</LI><LI> promoter RDP part</LI></OL><P>Because we're using four different promoters, each of the three precursor sets will exist of four different precursor constructs, that only differ in their promoter part.
</P></TD></TR></TBODY></TABLE></DIV><P>
The picture below illustrates how we designed the assembly of our precursor sets. 
</P><DIV class="figraw figure-large col-md-6"><TABLE><TBODY><TR><TD><B>Assembly Strategy of the precursor plasmids</B>First, the RDP part carrying the RBS and CDS is assembled to the cap. After the terminator part has been added, the reaction mix is split up into four. Respectively one of the four different promoter parts is added to one of the four reaction mix fractions. After finishing the assembly with an appropriate cap, you will receive four different precursor plasmids from the four different reaction mixes.
<P>(<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23100">BBa_J23100</A>, <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23104">BBa_J23104</A>, <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23110">BBa_J23110</A> and <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A> represent the four different Anderson promoters)
</P></TD></TR></TBODY></TABLE></DIV><P>
In total, this strategy results in 12 different precursor plasmids:
</P><TABLE class="wikitable"><TBODY><TR><TH> Precursor </TH><TH> description
</TH></TR><TR><TD><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585210">BBa_K1585210</A>.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23100">BBa_J23100</A></TD><TD><I>mdh</I>.AP00 precursor
</TD></TR><TR><TD> BBa_K1585210.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23104">BBa_J23104</A></TD><TD><I>mdh</I>.AP04 precursor
</TD></TR><TR><TD> BBa_K1585210.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23110">BBa_J23110</A></TD><TD><I>mdh</I>.AP10 precursor
</TD></TR><TR><TD> BBa_K1585210.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A></TD><TD><I>mdh</I>.AP19 precursor
</TD></TR><TR><TD><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585211">BBa_K1585211</A>.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B1006">BBa_B1006</A>.BBa_J23100 </TD><TD><I>hps</I>.AP00 precursor
</TD></TR><TR><TD> BBa_K1585211.BBa_B1006.BBa_J23104 </TD><TD><I>hps</I>.AP04 precursor
</TD></TR><TR><TD> BBa_K1585211.BBa_B1006.BBa_J23110 </TD><TD><I>hps</I>.AP10 precursor
</TD></TR><TR><TD> BBa_K1585211.BBa_B1006.BBa_J23119 </TD><TD><I>hps</I>.AP19 precursor
</TD></TR><TR><TD><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585212">BBa_K1585212</A>.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B1002">BBa_B1002</A>.BBa_J23100 </TD><TD><I>phi</I>.AP00 precursor
</TD></TR><TR><TD> BBa_K1585212.BBa_B1002.BBa_J23104 </TD><TD><I>phi</I>.AP04 precursor
</TD></TR><TR><TD> BBa_K1585212.BBa_B1002.BBa_J23110 </TD><TD><I>phi</I>.AP10 precursor
</TD></TR><TR><TD> BBa_K1585212.BBa_B1002.BBa_J23119 </TD><TD><I>phi</I>.AP19 precursor
</TD></TR></TBODY></TABLE><P>
The resulting precursor plasmids have to be purified and cut with BsaI and NotI to convert them into new RDP parts. To prevent complications, we chose chloramphenicol as resistance marker for the precursor plasmids. Since we planed to use kanamycin as resistance marker in the monocistronic diversity library, the cut backbone fragments of the precursor plasmids would not lead to viable clones.
</P><P>
In the end, this is how the design of the final assembly of the monocistronic diversity library looks like: We introduce diversity by adding the precursor RDP parts of one type in equimolar amounts to the reaction. 
</P><DIV class="figraw figure-large col-md-6"><TABLE><TBODY><TR><TD><B>Final assembly design for the monocistronic diversity library</B><SPAN style="color:transparent">bla</SPAN><UL><LI><I>mdh</I> precursor mix: equimolar mix of the four different BBa_K1585210.Trp.BBa_J231XX precursor RDP parts</LI><LI><I>hps</I> precursor mix: equimolar mix of the four different BBa_K1585211.BBa_B1006.BBa_J231XX precursor RDP parts</LI><LI><I>phi</I> precursor mix: equimolar mix of the four different BBa_K1585212.BBa_B1002.BBa_J231XX precursor RDP parts</LI></UL><P>(#FO4B#: kanamycin cap, #XYD9#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A> RDP part, #ZR1Q#: <A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585213">BBa_K1585213</A>.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B0015">BBa_B0015</A> RDP part, #OZD1#: high copy cap)
</P></TD></TR></TBODY></TABLE></DIV><P>The assembly product is supposed to be transformed into an appropriate expression strain (e.g. <I>E. coli</I> BL21 Gold DE3). By testing the growth performance, the resulting transformants can be screened. Strains harboring more efficient methanol conversion plasmids are expected to perform better in presence of methanol than others.
</P><H1><SPAN class="mw-headline" id="Results">Results</SPAN></H1><P>The following table gives an overview on our achieved progress in creating precursor plasmids:
</P><UL><LI> Failure = no valid plasmid sequenced</LI><LI> Success = a valid plasmid without mutations was sequenced</LI></UL><TABLE class="wikitable"><TBODY><TR><TH> Precursor </TH><TH> Results </TH><TH> Plasmid ID
</TH></TR><TR><TD><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585210">BBa_K1585210</A>.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23100">BBa_J23100</A></TD><TD> Failure </TD><TD> -
</TD></TR><TR><TD> BBa_K1585210.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23104">BBa_J23104</A></TD><TD> Success </TD><TD> #OX44#
</TD></TR><TR><TD> BBa_K1585210.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23110">BBa_J23110</A></TD><TD> Failure </TD><TD> -
</TD></TR><TR><TD> BBa_K1585210.Trp*.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_J23119">BBa_J23119</A></TD><TD> Success </TD><TD> #DNRY#
</TD></TR><TR><TD><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585211">BBa_K1585211</A>.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B1006">BBa_B1006</A>.BBa_J23100 </TD><TD> Success </TD><TD> #ERZK#
</TD></TR><TR><TD> BBa_K1585211.BBa_B1006.BBa_J23104 </TD><TD> Failure </TD><TD> -
</TD></TR><TR><TD> BBa_K1585211.BBa_B1006.BBa_J23110 </TD><TD> Failure </TD><TD> -
</TD></TR><TR><TD> BBa_K1585211.BBa_B1006.BBa_J23119 </TD><TD> Failure </TD><TD> -
</TD></TR><TR><TD><A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_K1585212">BBa_K1585212</A>.<A rel="nofollow" class="external text" href="http://parts.igem.org/Part:BBa_B1002">BBa_B1002</A>.BBa_J23100 </TD><TD> Success </TD><TD> #931O#
</TD></TR><TR><TD> BBa_K1585212.BBa_B1002.BBa_J23104 </TD><TD> Success </TD><TD> #EZYZ#
</TD></TR><TR><TD> BBa_K1585212.BBa_B1002.BBa_J23110 </TD><TD> Success </TD><TD> #XW1Y#
</TD></TR><TR><TD> BBa_K1585212.BBa_B1002.BBa_J23119 </TD><TD> Success </TD><TD> #RABS#
</TD></TR></TBODY></TABLE><UL><LI> *Trp = trp terminator, RDP part provided by Synbiota  </LI></UL><P>
Although we successfully created all required basic RDP parts, we were not able to create all the precursor RDP parts to continue with the assembly of the diversity library. In fact, we did not have problems to assemble the precursors. The major problem we had to face were mutations within the promoter sequences.
</P><P>Synbiota recommends to use HPLC purified oligos for creating your own RDP part below 100 bp in length, but since we had to create lots of RDP parts and a limited budget, we decided to order mostly standard desalting oligos. This might be a reason, why many of our promoter sequences showed deletions and/or point mutations.
</P><P><B>A more detailed documentation about creating the RDP parts and sequencing results can be found under:</B></P><P><B><A href="/Team:Aachen/Notebook/Documentation/Methanol_Monocistronic_Diversity_Library" title="Team:Aachen/Notebook/Documentation/Methanol Monocistronic Diversity Library">Laboratory Notebook</A></B></P><H1><SPAN class="mw-headline" id="Outlook">Outlook</SPAN></H1><P>After characterizing the Mdh activity in our polycistronic strain and considering it's reduced growth rate, we think that the monocistronic expression strategy is worth exploring. Creating a plasmid with atuned expression levels of the genes will provide more knowledge about the interactions between the enzymes and can help searching for an optimal way to make bacteria take up methanol efficiently.
</P><H1><SPAN class="mw-headline" id="References">References</SPAN></H1><OL class="references"><LI id="cite_note-1"><SPAN class="mw-cite-backlink"><A href="#cite_ref-1">↑</A></SPAN><SPAN class="reference-text">Jack BR, Leonard SP, Mishler DM, Renda BA, Leon D, Suárez GA, Barrick JE. Predicting the Genetic Stability of Engineered DNA Sequences with the EFM Calculator. ACS Synth Biol. 2015 Aug 21;4(8):939-43. doi: 10.1021/acssynbio.5b00068. Epub 2015 Jul 1. PubMed PMID: 26096262.</SPAN></LI></OL></DIV><DIV class="hexagon-bg"><DIV class="hexagon"><DIV class="colorable fill"><CENTER><A href="#">▲</A></CENTER></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="footer"><DIV class="bar"><DIV class="bar-wrap"><DIV class="disclaimer"><A href="mailto:igem@rwth-aachen.de">Contact</A></DIV><DIV class="copyright">CC-BY-SA iGEM Aachen 2015</DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>